{"entity":{"id":"anakinra","kind":"drug","name":"Anakinra","aka":[],"tldr":"Anakinra is an anti-inflammatory injection approved for arthritis and rare inflammatory diseases. After CAR-T cell therapy it is used to calm a severe inflammatory reaction (IEC-HS) and as a third-line option when cytokine release syndrome does not settle.","summary":"The Kineret label covers rheumatoid arthritis, neonatal-onset multisystem inflammatory disease (a cryopyrin-associated periodic syndrome) and deficiency of the interleukin-1 receptor antagonist. In the ASTCT consensus on immune effector cell-associated HLH-like syndrome (Hines 2023), \"Anakinra was recommended as a first-line agent\", and \"Therapy should generally be initiated with corticosteroids +/− anakinra prior to development of life-threatening complications\". SITC 2020 says that if cytokine release syndrome does not improve after two doses of tocilizumab and steroids, third-line agents including anakinra, siltuximab and high-dose methylprednisolone should be considered (level of evidence 4). Its use in these settings is off-label. The BLA was first approved on 14 November 2001.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Anakinra","links":[{"label":"US label (DailyMed): Kineret","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d74915-6606-4570-9c52-c4001d3177de"},{"label":"Hines et al., Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (ASTCT, Transplant Cell Ther 2023)","url":"https://doi.org/10.1016/j.jtct.2023.03.006"},{"label":"Maus et al., SITC clinical practice guideline on immune effector cell-related adverse events (J Immunother Cancer 2020)","url":"https://doi.org/10.1136/jitc-2020-001511"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["tocilizumab"],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["crs","iec-hs"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Kineret","modality":"Interleukin-1 receptor antagonist (recombinant protein, injection)","supportive":true,"mechanism":"A recombinant interleukin-1 receptor antagonist that blocks IL-1 signalling.","approvals":[{"region":"US","year":2001,"indication":"Rheumatoid arthritis; neonatal-onset multisystem inflammatory disease; deficiency of interleukin-1 receptor antagonist","note":"Year is the original BLA 103950 approval (Drugs@FDA); oncology use is off-label"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/anakinra/","neighbours":{"drug":[{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"term":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"},{"id":"iec-hs","kind":"term","name":"IEC-HS (immune effector cell-associated HLH-like syndrome)","route":"/terms/iec-hs/"}]}}